Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression.

Proteins with expanded polyglutamine (polyQ) tracts have been linked to neurodegenerative diseases. One common characteristic of expanded-polyQ expression is the formation of intracellular aggregates (IAs). IAs purified from polyQ-expressing cells were dissociated and studied by protein blot assay and mass spectrometry to determine the identity, condition, and relative level of several proteins sequestered within aggregates. Most of the sequestered proteins comigrated with bands from control extracts, indicating that the sequestered proteins were intact and not irreversibly bound to the polyQ polymer. Among the proteins found sequestered at relatively high levels in purified IAs were ubiquitin, the cell cycle-regulating proteins p53 and mdm-2, HSP70, the global transcriptional regulator Tata-binding protein/TFIID, cytoskeleton proteins actin and 68-kD neurofilament, and proteins of the nuclear pore complex. These data reveal that IAs are highly complex structures with a multiplicity of contributing proteins.

Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain.

Expanded polyglutamine (polyQ) tracts have been linked to a new class of human disease characterized by psychiatric/motor syndromes associated with specific patterns of neurodegeneration. We have used a direct viral approach to locally express expanded polyglutamine tracts fused to the green fluorescent protein (97Q-GFP) in the adult rat brain. We show that intrastriatal expression of 97Q-GFP causes the rapid formation of fibrillar, cytoplasmic, and ubiquitinated nuclear aggregates in neurons. 97Q-GFP expression also results in a specific temporal pattern of cell death in the striatum. Co-infection studies suggest that high level 97Q-GFP-expressing cells die during the first month, whereas low level 97Q-GFP-expressing neurons persist for up to 6 months after infection. These data indicate that cumulative expression of polyQ repeats throughout the life of the animal is not required to induce neuronal death, but rather acute overexpression of polyQ is toxic to adult neurons in vivo.

Prenatal gene therapy: can the technical hurdles be overcome?

Fifty years ago, a medical breakthrough in the prenatal diagnosis of genetic disorders was made with the introduction of amniocentesis. Until recently, there was little hope that diseases diagnosed in utero could be treated before birth. Today, prenatal gene therapy is emerging as a new concept for treating pre- and postnatal manifestations of genetic diseases and developmental disorders. Research studies have generated a degree of optimism by demonstrating the feasibility of fetal gene transfer. Nevertheless, enthusiasm is tempered by the considerable technical and ethical issues raised by such studies. Undoubtedly, the future of prenatal gene transfer as a therapeutic approach for birth defects mostly depends on addressing and overcoming these concerns.

High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor.

Our studies of the Bombyx mori ecdysone receptor (BE) revealed that, unlike the Drosophila melanogaster ecdysone receptor (DE), treatment of BE with the ecdysone agonist tebufenozide stimulated high level transactivation in mammalian cells without adding an exogenous heterodimer partner. Gel mobility shift and transfection assays with both the ultraspiracle gene product (Usp) and retinoid X receptor heterodimer partners indicated that this property of BE stems from significantly augmented heterodimer complex formation and concomitant DNA binding. We have mapped this "gain of function" to determinants within the D and E domains of BE and demonstrated that, although the D domain determinant is sufficient for high affinity heterodimerization with Usp, both determinants are necessary for high affinity interaction with retinoid X receptor. Modified BE receptors alone used as replication-defective retroviruses potently stimulated separate "reporter" viruses in all cell types examined, suggesting that BE has potentially broad utility in the modulation of transgene expression in mammalian cells.

Gene transfer to the rodent placenta in situ. A new strategy for delivering gene products to the fetus.

The delivery of biologically active factors to the developing mammalian embryo by in utero gene transfer has generated considerable interest but limited success. The chorioallantoic placenta is a potential alternative target for providing therapeutic transgenes to the fetus during gestation. We demonstrate that somatic gene transfer to the midgestation rat placenta may be efficiently accomplished in situ through the implantation of a variety of genetically modified cells with different antigenic and growth properties. Ex vivo-modified cells survived and retained transgene expression until term. Proteins secreted from the transplanted cells were detectable within the fetal trunk blood. These studies suggest that gene transfer to the placenta may be a useful tool for answering questions of both embryonic and placental development and providing therapeutic proteins during gestation for amelioration of diseases with onset during embryonic life.

The use of nonneuronal cells for gene delivery.

The implantation of genetically engineered nonneuronal cells can provide an effective method for achieving localized delivery of discrete molecules to the CNS or for providing substrates for regrowth of neural structures. Most primary nonneuronal cells have the advantage of being easily obtainable from the prospective host for ex vivo retrovirus-mediated genetic manipulation (most will be mitotic in culture) and reimplantation as an autologous graft (circumventing the problem of immune rejection). As primary cells, they are unlikely to be tumorigenic. The most vexing problem for such systems remains the apparent loss of transgene expression from viral promoters after prolonged periods of engraftment. Much effort is currently being directed at optimizing sustained transgene expression by varying the promoters, by varying the cell types to be engineered, or by regulating expression by enhancing promoter function or substrate availability. While nonneuronal cells are excellent vehicles for achieving passive delivery of substances to the CNS, they lack the ability to incorporate into the host cytoarchitecture in a functional manner (e.g., make synaptic contacts). For this reason, not only may certain essential circuits not be re-formed, but the regulated release of certain substances through feedback loops may be missing. While apparently unimportant for some substances (e.g., ACh), for others (e.g., NGF), their unregulated, inappropriate, excessive, or ectopic release may actually be inimical to the host. Furthermore, the loss of foreign gene expression (the bane of gene therapy) may leave engineered nonneural cells incapacitated, whereas donor tissue originating from brain may intrinsically produce various CNS factors allowing correction to proceed despite inactivation of the introduced gene. In fact, CNS-derived tissue may provide as-yet-unrecognized endogenous neuralspecific substances which are equally as beneficial to the host as the gene in question. Thus, future developments in gene delivery to the brain for some conditions may emphasize using neurons or neural progenitors for ex vivo genetic manipulation (Fisher, 1997) and refining techniques for the direct injection of therapeutic genes into neurons in vivo (see Snyder and Fisher, 1996). For a wide variety of conditions, however, using nonneuronal cellular vehicles or even nonbiologic synthetic vehicles may be efficient, effective, and safe strategies for the passive delivery of therapeutic molecules to discrete regions of the CNS. In fact, this approach may come closer than any other to immediate human applications.

Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration.

Gene therapy may be a useful means of delivering substances to the brain that are capable of preventing neuronal degeneration. In the present experiment, we determined whether intraparenchymal transplants of primary autologous cells genetically modified to produce nerve growth factor (NGF) would prevent injury-induced degeneration of cholinergic neurons. Cultured primary monkey fibroblasts were genetically modified to produce human NGF, and secreted 13.2 ng NGF/10(6) cells/h in vitro. Adult monkeys then underwent fornix transections to induce degeneration of basal forebrain cholinergic neurons, and received autologous grafts of either NGF-producing or control, beta-galactosidase-producing fibroblasts directly into the basal forebrain region. One month later, 61.7 +/- 8.9% of cholinergic neurons remained indentifiable in NGF-graft recipients compared to 26.2 +/- 5.0% in control graft recipients (P < 0.02). Neuronal protection correlated with the accuracy of graft placement: up to 92% protection from neuronal degeneration occurred when NGF-secreting grafts were accurately placed immediately adjacent to injured neurons. Thus, intraparenchymal NGF delivery to the adult primate brain by gene transfer can prevent the degeneration of basal forebrain cholinergic neurons. Gene therapy can target intraparenchymal brain sites for regionally specific neurotrophin delivery, thereby avoiding limitations imposed by diffusion of substances across the blood-brain barrier and through CNS parenchyma, while avoiding adverse effects of neurotrophic factors delivered in a non-directed manner to the central nervous system. The delivery of NGF by gene transfer to the brain merits further study as a means of preventing cholinergic neuronal degeneration in human disorders such as Alzheimer's disease.

Regional differences in responsiveness of adult CNS axons to grafts of cells expressing human neurotrophin 3.

Neurotrophin 3 (NT3) belongs to the neurotrophin family, which also includes nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 4/5. NT3 mRNA is widely expressed in the rodent nervous system, but the physiological function of the native protein is still unclear. Genetically modified cell lines that produce physiological amounts of NT3 can provide a useful tool in the elucidation of the NT3 effects in the adult central nervous system (CNS). Genetically modified rat primary skin fibroblasts expressing and secreting human NT3 (hNT3) were prepared and characterized. In vitro, cell lines derived from different retroviral constructs expressed hNT3 mRNA, as determined by PCR and RNA blot analysis. Secretion of biologically active hNT3 was confirmed by specific elicitation of neurite outgrowth from cultured chick primary sympathetic and sensory neurons and from rat fetal locus coeruleus neurons in the presence of hNT3-producing cell conditioned media. In vivo, implanted fibroblasts survived well up to the maximal experimental time points of 6 weeks (brain) and 4 weeks (spinal cord) and continued to express hNT3 mRNA in vivo. As early as 2 weeks postgrafting, specific sprouting of host sensory neurites in response to hNT3-producing grafts was observed in the spinal cord. In contrast, hNT3-producing cerebral grafts did not induce a sprouting response different from that observed with control grafts. These findings establish the existence of a regionally different responsiveness of the CNS axons to local hNT3 overexpression.

Age-related changes in parvalbumin- and GABA-immunoreactive cells in the rat septum.

The calcium binding protein parvalbumin is present in GABAergic neurons of the medial septum-diagonal band of Broca (MS-DBB) region that project to the hippocampal formation. We examined the distribution pattern, the number, and the morphological features of the parvalbumin-containing cells (parv+) in the MS-DBB region of 2- to 3-, 8- to 9-, 15- to 16-, and 26- to 27-month-old Sprague-Dawley rats. A significant reduction in the number of parv+ cells was observed as a function of age. The mean somal area of the parv+ cells was significantly reduced in the 26- to 27-month-old rats. A significant reduction in the number of parv+ cells was also observed in the 26- to 27-month-old rats in the cingulate cortex, but not in the striatum or the hippocampal formation. No significant age-related changes were observed in the number of the GABA-immunoreactive cells in the MS-DBB region nor in the cingulate cortex. In conclusion, there is an age-related decrease in the number of parv+ cells, with no change in the number of GABA-immunoreactive cells in the MS-DBB region of the rat. Because GABA and parvalbumin are colocalized in the MS-DBB neurons, the results suggest that the level of parvalbumin is decreased, but that the cells are not lost.

Somatic gene transfer to the adult primate central nervous system: in vitro and in vivo characterization of cells genetically modified to secrete nerve growth factor.

Somatic gene transfer offers a means of delivering substances to the central nervous system (CNS) in a regionally specific, high-dose, chronic and well-tolerated manner. Studies in rats have shown that genetically modified cell grafts can prevent neuronal degeneration and promote functional recovery after injury and can improve cognitive function in aged subjects. To assess the potential utility of somatic gene transfer techniques in primate models, retroviral vectors were used to modify genetically monkey and human primary skin fibroblasts to produce and secrete human nerve growth factor (NGF). In vitro, all cell types produced NGF and sustained this production through cell growth to confluency, as determined by both Northern blot analysis and ELISA. Adult human fibroblasts produced as much NGF as did young human fibroblasts. Monkey fibroblasts genetically modified to produce NGF were then grafted to intact adult rhesus and cynomolgous monkey brains. Among nine primates that received a total of 76 grafts, surviving cells were found in all subjects up to the maximal experimental timepoint of 6 months. Cholinergic fibres from the host brain penetrated NGF-secreting grafts up to 6 months after grafting, but showed little penetration in control grafts lacking the NGF gene. Autografts survived better than allografts. These findings indicate that both human and primate fibroblasts can be transduced to produce and secrete NGF, can maintain this production whether in a growing or quiescent state and can elicit robust sprouting responses when primate fibroblasts are grafted to the adult brain. Cells genetically modified to produce trophic factors are a useful model for studying in vitro and in vivo CNS plasticity and for testing potential therapies for neurodegenerative conditions.

Protein SP40,40-like Immunoreactivity in the Rat Brain: Progressive Increase With Age.

The pattern of distribution of SP40,40-like immunoreactive structures has been studied in the rat brain using a well-characterized polyclonal antibody raised against the SP40,40 protein. Protein SP40,40 is the human counterpart of the rat sulphated glycoprotein 2, whose mRNA shows widespread expression in the developing and mature brain. In young adult rats few immunoreactive structures were observed. Some immunoreactive neurons were found in the cingulate cortex, the arcuate and perifornical hypothalamic nuclei, as well as glial labelling in the hypothalamus. A striking increase in the number of immunoreactive cells was observed as a function of age. In 20 - 22-month-old rats, numerous immunoreactive cells were observed in the cingulate cortex, several thalamic and hypothalamic nuclei, the red nucleus, olivary nuclei, superior colliculus, and many cranial nerve nuclei. Whereas the immunoreactivity was restricted to a diffuse labelling of the cell bodies and processes in young rats, other forms of labelling were observed in aged rats: punctate cytoplasmic labelling and intensely stained granules with no visible cell membrane. A further increase in the density of the immunoreactive material was observed in 30 - 31-month-old rats. Double labelling experiments demonstrated that the SP40,40 immunoreactivity was almost exclusively located in neurons and not in glial cells (with the exception noted above). The distribution of SP40,40 immunoreactivity in aged rats did not coincide with the distribution of the microtubule-associated tau protein, OX42 or lipofuscin.

Age-related changes in galanin-immunoreactive cells of the rat medial septal area.

Age-related changes in the cholinergic cells have been reported in the rat medial septal area. The neuropeptide galanin is colocalized with acetylcholine in the majority of the medial septal neurons. To assess possible age-related changes in the galanin-containing septal cells, we have examined, with immunohistochemical methods, the distribution pattern, density, and morphological features of galanin-containing cells in the rat medial septal nucleus (MS) and the nucleus of the diagonal band of Broca (DBB) in 1, 3-6, 9-12, 16-18, 24-27, and 28-30 month-old rats. A morphometric computerized analysis was also performed. In addition, the intensity of the immunolabelling was measured by densitometry. Galanin-like immunoreactivity (galanin-LI) was present in both the MS and the DBB. Our results clearly indicate a progressive age-related decrease in the number of galanin-positive cells throughout the MS-DBB complex. Our quantitative study revealed a significant loss of galanin-positive cells in the MS-DBB complex of 16-18 (50.4%), 24-27 (52.3%), and 28-30 (52.4%) month-old rats compared to 3-6 month-old animals. A non-significant reduction (28.6%) in galanin-LI cell number was observed in 3-6 month-old rats compared to 1 month-old animals. The morphometric analysis demonstrated a significant reduction (18%) in the surface of galanin-positive cells remaining in the 28-30 month-old group. Furthermore, a significant decrease in the immunolabelling intensity was consistently observed in animals of 16 month-old and older. To determine whether changes in galanin-positive cells were associated with cholinergic changes, the number of cells stained for acetylcholinesterase (AChE) was estimated in 3-6, 9-12, 16-18, and 24-27 month-old rats. There was a 43% decrease in the number of AChE-positive cells and a 71% loss of galanin-positive cells in 24-27 month-old rats compared to 3-6 month-old. The galanin-cell loss in the medial septal area was therefore associated with a parallel, although smaller, cholinergic septal cell loss.

Senile dementia of the Alzheimer type: is there a correlation between entorhinal cortex and dentate gyrus lesions?

Senile plaques (SP) are one of the neuropathological hallmarks of senile dementia of the Alzheimer type (SDAT). In 14 patients affected with SDAT (over 74 years of age), thioflavine S, Tau and acetylcholinesterase (AChE) stainings demonstrated an increased density of SP in the outer two thirds of the dentate gyrus molecular layer. However, a wide range of SP density was observed among the cases. The molecular layer of the dentate gyrus is one of the termination site of the perforant pathway that originates in layers II and III of the entorhinal cortex. We have found that the number of AChE-, thioflavine S- and Tau-positive SP that accumulate in the dentate gyrus is positively correlated with the density of thioflavine S-stained neurofibrillary tangles in layers II and III of the entorhinal cortex. In contrast, a similar correlation is not found when using Tau immunolabeling of the entorhinal tangles. These observations show an association between the accumulation of AChE-positive SP in the dentate molecular layer and the lesions of the perforant pathway. Furthermore, they suggest that the density of SP in the dentate gyrus correlates with the late stages of neurofibrillary tangles formation (thioflavine S positive), but not with the early stages (Tau positive).

[Comparative study in aged rats of behavioral deficiencies and morphometrical modifications of galanin containing neurons in the medial septal area]. / Etude comparative chez le rat âgé des déficits comportementaux et des modifications morphométriques des neurones contenant de la galanine dans la région septale médiane.

Age-related alterations in cued-training and place-training tasks were evaluated and compared to alterations in the galanin-like (GAL-LI) immunoreactive neurons in the medial septal area of the rat. Young adult (4 months) and aged (25-26 months) male Sprague-Dawley rats performed a modified version of the Morris water maze task. Immunohistochemical and morphometric techniques were used to analyse the distribution, density and morphology of GAL-LI neurons in the medial septum-diagonal band of Broca (MS-DBB) complex. A large variability in performance of the aged rats was evident, with the majority of aged rats exhibiting impaired performance on both parts of the task as compared to the young rats. In addition, there was a significant loss of GAL-LI cells in the MS-DBB complex, a significant reduction of the immunolabeling intensity of the subsisting GAL-LI cells and a non-statistically significant loss of septo-hippocampal GAL-LI neurons. There were no statistically significant correlations between the behavioral performances and the quantitative and qualitative modifications of GAL-LI cell bodies.

Loss of Calbindin-28K Immunoreactivity in Hippocampal Slices from Aged Rats: a Role for Calcium?

Calbindin-28K (CaBP) is a calcium-binding protein widely distributed in the brain. This protein appears to be involved in the sequestration and the translocation of intracellular free calcium. In this study, we have examined the distribution pattern of the structures immunoreactive for CaBP in the hippocampal formation from slices of young (4 months) and aged (24 - 27 months) rats previously submitted to electrophysiological measurements. We demonstrated a marked loss in the number of pyramidal cells immunoreactive for CaBP in aged rats as compared to young rats. A consistent decrease in the staining intensity was also revealed by optical density measurements. Some experiments have suggested that calcium homeostasis is modified in hippocampal neurons of aged rats. The loss of CaBP-like immunoreactivity (CaBP-LI) labelling could result from an increase in intracellular calcium concentrations. To support this hypothesis, we showed that in young rats (i) the CaBP-LI was enhanced in pyramidal neurons when the slice was preincubated in a calcium-free medium, and (ii) CaBP-LI was strongly decreased when the slice was preincubated in a high-calcium medium (5 mM) and when the entry of calcium into the cell was increased by a short application of an excitatory amino acid in the medium. Our results suggest that the loss of CaBP-LI in the hippocampus of aged rats could be due to an increase in intracellular calcium concentration. Preliminary observations of hippocampal slices at different times after induction of long-term potentiation (LTP) failed to show significant changes in CaBP immunoreactivity, suggesting that this calcium-binding protein is not directly involved in LTP processes.

Medial septal neurons containing N-acetyl-aspartyl-glutamate-like immunoreactivity project to the hippocampal formation in the rat.

We have examined the distribution of N-acetyl-aspartyl-glutamate (NAAG)-like immunoreactive cell bodies in the medial septal nucleus and the nucleus of the diagonal band of Broca of the rat and assessed the involvement of these cells in the septo-hippocampal pathway. A series of experiments was carried out using immunohistochemistry alone or combined with the retrograde transport of a protein-gold complex injected into the dorsal hippocampal formation. A large number of NAAG-positive cells was observed in the medial septum and the diagonal band. Quantitative analysis revealed that 26% of the NAAG-like immunoreactive cells in the medial septum project to the dorsal hippocampal formation. These results demonstrate that the dipeptide NAAG is a major component of the rat septo-hippocampal pathway.

125I-[Tyr0,D-Trp8]somatostatin-14 binding sites in the locus coeruleus of the rat are located on both ascending and descending projecting noradrenergic cells.

Radioautographic determinations of 125I-[Tyr0,D-Trp8]somatostatin-14 (125I-SRIF) binding sites were performed on frozen serial sections of the locus coeruleus (LC) of control rats and of rats subjected to either bilateral microinjections of 6 hydroxydopamine (6-OHDA) into the LC or unilateral microinjection into the ascending noradrenergic bundles. These experiments were performed in order to determine whether 125I-SRIF binding was localized to noradrenergic-containing cells and in which regions the cells which contain the binding sites are projecting. The extent of the lesions was assessed by measuring norepinephrine (NE) levels in the hippocampus (88% decrease as compared to sham-operated animals) for bilateral LC lesions and in the frontal cortex (87% reduction vs. contralateral side) for unilateral bundle lesions. In control rats, 125I-SRIF binding sites were restricted to the boundaries of the LC and followed closely the distribution of tyrosine hydroxylase-labeled cells. Three weeks after bilateral injections of 6-OHDA, 125I-SRIF binding decreased by 79% in all regions of the LC. In contrast, unilateral destruction of the ascending noradrenergic bundles resulted in a moderate decrease only in the middle part of the LC with a more important effect in the dorsal (55%) than in the ventral (24%) portion of the nucleus. These data demonstrate that: 1) most SRIF receptors in the LC are located in the vicinity of NE-containing cell bodies and 2) NE-containing cells bearing SRIF receptors project to the forebrain as well as to other terminal areas located more caudally in the brain. These data suggest a general role for SRIF in the control of the multiple functions of the LC.

Neuronal localization of the nerve growth factor precursor-like immunoreactivity in the rat brain.

The distribution of the nerve growth factor precursor(proNGF)-like immunoreactivity was examined in the adult rat brain with affinity-purified antisera directed against synthetic peptides that reproduce sequences of the precursor protein. Immunoreactivity was localized in defined areas of the neocortex, hippocampal formation, thalamus/hypothalamus, striatum, olfactory bulb, pons and spinal cord, which are regions previously reported to contain NGF mRNA. Interestingly, immunoreactivity was also observed in the septum and diagonal band of Broca known to contain very low NGF mRNA levels. Using immunohistochemical methods combined with the retrograde transport of a protein gold complex we demonstrate that proNGF-like immunoreactivity is localized within neuronal cell bodies, in the cortex, hippocampus and septum. These results suggest that the immunological approach may not only identify NGF-synthesizing cells, but also cells which may accumulate proNGF or some cleavage products by an uptake mechanism.